Jan Menne

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus et al. · New England Journal of Medicine · 2013 · 1.6K citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Loss of Caveolae, Vascular Dysfunction, and Pulmonary Defects in Caveolin-1 Gene-Disrupted Mice

Marek Dráb, Paul Verkade, Marlies Elger et al. · Science · 2001 · 1.6K citations

Life Sciences, Cell Biology, Molecular Biology +17

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

Fádi Fakhouri, Maryvonne Hourmant, Josep M. Campistol et al. · American Journal of Kidney Diseases · 2016 · 308 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

Jan Menne, Martin Nitschke, Robert Stingele et al. · BMJ · 2012 · 306 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +9

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16